Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.30+0.18 (+2.94%)
Close on Nov 18, 2026Market cap $190.61MP/E –Yield –
Cartesian Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cartesian Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.48M. For fiscal 2025 it was $2.80M, down 92.8% from the year before. Over ten years it grew -7.4% a year on average. The highest annual figure on record is $110.78M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80M | -92.8% |
| FY2024 | Dec 31, 2024 | $38.91M | +49.6% |
| FY2023 | Dec 31, 2023 | $26.00M | -76.5% |
| FY2022 | Dec 31, 2022 | $110.78M | +30.2% |
| FY2021 | Dec 31, 2021 | $85.08M | +412.6% |
| FY2020 | Dec 31, 2020 | $16.60M | +148.6% |
| FY2019 | Dec 31, 2019 | $6.68M | +639.4% |
| FY2018 | Dec 31, 2018 | $903.00K | +336.2% |
| FY2017 | Dec 31, 2017 | $207.00K | -97.4% |
| FY2016 | Dec 31, 2016 | $8.08M | +34.5% |
| FY2015 | Dec 31, 2015 | $6.01M | +97.7% |
| FY2014 | Dec 31, 2014 | $3.04M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $78.00K | -92.9% |
| Q4 FY2025 | Dec 31, 2025 | $947.00K | +144.7% |
| Q3 FY2025 | Sep 30, 2025 | $452.00K | -98.6% |
| Q2 FY2025 | Jun 30, 2025 | $298.00K | -94.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.10M | -86.7% |
| Q3 FY2024 | Sep 30, 2024 | $387.00K | -94.1% |
| Q2 FY2024 | Jun 30, 2024 | $33.45M | +537.2% |
| Q1 FY2024 | Mar 31, 2024 | $5.84M | -1.7% |
| Q4 FY2023 | Dec 31, 2023 | $8.27M | -50.8% |
| Q3 FY2023 | Sep 30, 2023 | $6.55M | -68.4% |
| Q2 FY2023 | Jun 30, 2023 | $5.25M | -86.6% |
| Q1 FY2023 | Mar 31, 2023 | $5.94M | -82.5% |
| Q4 FY2022 | Dec 31, 2022 | $16.80M | -43.9% |
| Q3 FY2022 | Sep 30, 2022 | $20.71M | -15.2% |
| Q2 FY2022 | Jun 30, 2022 | $39.27M | +99.7% |
| Q1 FY2022 | Mar 31, 2022 | $34.00M | +207.7% |
| Q4 FY2021 | Dec 31, 2021 | $29.94M | +150.5% |
| Q3 FY2021 | Sep 30, 2021 | $24.43M | +425.8% |
| Q2 FY2021 | Jun 30, 2021 | $19.66M | – |
| Q1 FY2021 | Mar 31, 2021 | $11.05M | – |
| Q4 FY2020 | Dec 31, 2020 | $11.95M | +79.6% |
| Q3 FY2020 | Sep 30, 2020 | $4.65M | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | -100.0% |
| Q1 FY2020 | Mar 31, 2020 | $0 | -100.0% |
| Q4 FY2019 | Dec 31, 2019 | $6.65M | +636.9% |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $13.00K | – |
| Q1 FY2019 | Mar 31, 2019 | $10.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $903.00K | +5211.8% |
| Q3 FY2018 | Sep 30, 2018 | $0 | -100.0% |
| Q2 FY2018 | Jun 30, 2018 | $0 | -100.0% |
| Q1 FY2018 | Mar 31, 2018 | $0 | -100.0% |
| Q4 FY2017 | Dec 31, 2017 | $17.00K | -99.4% |
| Q3 FY2017 | Sep 30, 2017 | $27.00K | -97.4% |
| Q2 FY2017 | Jun 30, 2017 | $26.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $137.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $2.93M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.05M | – |
See a number that looks wrong?